Prediction and Early Detection of Response by NMR Spectroscopy and Imaging

TY - JOUR

T1 - Prediction and Early Detection of Response by NMR Spectroscopy and Imaging

AU - Lee, Seung-Cheol

AU - Arias-Mendoza, Fernando

AU - Poptani, Harish

AU - Delikatny, E James

AU - Wasik, Mariusz

AU - Marzec, Michal

AU - Schuster, Stephen J

AU - Nasta, Sunita D

AU - Svoboda, Jakub

AU - O'Connor, Owen A

AU - Smith, Mitchell R

AU - Glickson, Jerry D

PY - 2012/1

Y1 - 2012/1

N2 - Pretreatment 31 P magnetic resonance (MRS) when applied to a cadre of 41 non-Hodgkin's lymphoma (NHL) regardless of disease type or stage and regardless of therapeutic regimen, was able to predict about two thirds of the patients that exhibited a complete response (CR; sensitivity 0.92, specificity 0.79). However, when the study was restricted to 27 NHL patients with the most common form of NHL, diffuse large B-cell lymphoma, all of whom were treated with RCHOP (rituximab plus CHOP chemotherapy) or "RCHOP-like" therapy, was able to predict CR and non-CR with a sensitivity of 1.0 and specificity of 0.90 by Fisher analysis). Patients predicted not to exhibit a CR could be directed to more vigorous therapeutic regimens followed by bone marrow transplantation or to experimental new therapeutic agents. This article highlights a general strategy for non-invasively monitoring response to inhibitors of specific signal transduction pathways by monitoring the corresponding metabolic pathway that is modified by signal transduction inhibition.

AB - Pretreatment 31 P magnetic resonance (MRS) when applied to a cadre of 41 non-Hodgkin's lymphoma (NHL) regardless of disease type or stage and regardless of therapeutic regimen, was able to predict about two thirds of the patients that exhibited a complete response (CR; sensitivity 0.92, specificity 0.79). However, when the study was restricted to 27 NHL patients with the most common form of NHL, diffuse large B-cell lymphoma, all of whom were treated with RCHOP (rituximab plus CHOP chemotherapy) or "RCHOP-like" therapy, was able to predict CR and non-CR with a sensitivity of 1.0 and specificity of 0.90 by Fisher analysis). Patients predicted not to exhibit a CR could be directed to more vigorous therapeutic regimens followed by bone marrow transplantation or to experimental new therapeutic agents. This article highlights a general strategy for non-invasively monitoring response to inhibitors of specific signal transduction pathways by monitoring the corresponding metabolic pathway that is modified by signal transduction inhibition.

KW - Journal Article

U2 - 10.1016/j.cpet.2011.12.007

DO - 10.1016/j.cpet.2011.12.007

M3 - Journal article

C2 - 22737093

SN - 1556-8598

VL - 7

SP - 119

EP - 126

JO - P E T Clinics

JF - P E T Clinics

IS - 1

ER -